Drugs / intepirdine
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00551772 | Aug 2007 → ? | Alzheimer disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 26 trials · 3 missed | ||||||
| Phase 2 | NCT02910102 | Oct 2016 → Nov 2017 | Alzheimer disease, Lewy body dementia, Parkinson disease | Axovant Sciences Ltd. | Completed | Missed primary |
| Phase 2 | NCT02669433 | Jan 2016 → Dec 2017 | Lewy body dementia | Axovant Sciences Ltd. | Completed | Missed primary |
| Phase 2 | NCT00708552 | Jul 2008 → Mar 2010 | Alzheimer disease | GlaxoSmithKline | Completed | Missed primary |
| Phase 2 | NCT00710684 | Jul 2008 → May 2010 | Alzheimer disease | GlaxoSmithKline | Completed | Mixed |
| Phase 2 | NCT00348192 | May 2006 → ? | Alzheimer disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00224497 | Sep 2005 → ? | Alzheimer disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02928445 | Oct 2016 → Feb 2018 | Lewy body dementia | Axovant Sciences Ltd. | Terminated | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT02586909 | Apr 2016 → Mar 2018 | Alzheimer disease | Axovant Sciences Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT02585934 | Oct 2015 → Sep 2017 | Alzheimer disease | Axovant Sciences Ltd. | Completed | Missed primary |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | intepirdine | “This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.” NCT02910102 ↗4“This study seeks to confirm a demonstrated treatment effect of intepirdine (RVT-101) as an adjunctive therapy to donepezil for the treatment of subjects with Alzheimer's disease.” NCT02585934 ↗ “Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study” NCT02669433 ↗ “intepirdine (RVT-101)” NCT02928445 ↗ “intepirdine (RVT-101)” NCT02586909 ↗ |
| Known as | GSK-742457 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1083390 ↗ |
| Known as | Intepirdina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1083390 ↗ |
| Known as | RVT-101 | “intepirdine (RVT-101)” NCT02586909 ↗ |
| Known as | SB742457 | “Two previous studies of SB742457, a 5-hydroxytryptamine (5-HT6) receptor antagonist, suggested the efficacy of improvements in cognition and global outcome in Alzheimer's disease (AD).” PMID 29854923 ↗ May 2015 |
| Action | Inhibit | “Two previous studies of SB742457, a 5-hydroxytryptamine (5-HT6) receptor antagonist, suggested the efficacy of improvements in cognition and global outcome in Alzheimer's disease (AD).” PMID 29854923 ↗ May 20151“Serotonin 6 (5-HT6) receptor antagonist” CHEMBL1083390 ↗ |
| Modality | Small molecule | — CHEMBL1083390 ↗ |
| Route | Oral | “once daily, oral, 35 mg tablets” NCT02585934 ↗ |
| Target | HTR6 | “Serotonin 6 (5-HT6) receptor antagonist” CHEMBL1083390 ↗ |